NCT01437059View on ClinicalTrials.gov

Trial to Evaluate Safety and Tolerability of ALN-PCS02 in Subjects With Elevated LDL-Cholesterol (LDL-C)

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

March 31, 2012

Study Completion Date

September 30, 2012

Conditions
Elevated LDL-Cholesterol (LDL-C)
Interventions
DRUG

ALN-PCS02

Dose levels between 15 and 400 μg/kg by intravenous (IV) infusion

DRUG

Sterile Normal Saline (0.9% NaCl)

Calculated volume to match active comparator

Trial Locations (2)

LS2 9LH

Clinical Site, Leeds

SE1 1YR

Clinical Site, London

Sponsors
All Listed Sponsors
lead

Alnylam Pharmaceuticals

INDUSTRY